FDA approves new cancer drugs from Pfizer, Medivation/Astellas

Share this article:
Pfizer Oncology racked up its third FDA approval of a new drug in 13 months as the agency green lighted leukemia drug Bosulif (bosutinib).

The drug is indicated for previously-treated Philadelphia chromosome positive chronic myelogenous leukemia (CML). The trial included patients previouisly treated with imatinib (Gleevec) or imatinib plus at least one second-generation tyrosine kinase inhibitor, and Pfizer noted that around a third of patients receiving the Novartis drug as initial therapy “do not achieve an optimal response,” while only half of those who ultimately require second-generation TKIs see good outcomes. An estimated 26,000 Americans are living with CML, and more than 5,000 new cases are diagnosed each year in the US.

“As the first therapy in our growing hematology portfolio to receive approval by the FDA, Bosulif exemplifies Pfizer's commitment to bringing meaningful new medicines to patients with hematologic cancers,” said Pfizer Oncology VP of clinical development and medical affairs Mace Rothenberg. “We believe many doctors and CML patients will find this treatment to be a welcome addition, offering a distinct adverse event profile and a convenient once-daily dosing regimen.

FDA also approved Medivation/Astellas Pharma prostate cancer drug Xtandi (enzalutamide), indicated for treatment of metastatic castration-resistant prostate cancer that has failed treatment with Sanofi's Taxotere. The drug was developed by Medivation but Astellas will comarket the drug in the US and has marketing rights for the rest of the world.  
Share this article:

Email Newsletters

More in News

BI rethinks hepatitis business, posts 2013 results

BI rethinks hepatitis business, posts 2013 results

Boehringer Ingelheim says it is no longer pursuing an interferon-free combination of faldaprevir and deleobuvir.

Roche wraps quarter with two fewer pipeline medications

Roche wraps quarter with two fewer pipeline medications

Roche also announced first-quarter sales shrank 1%.

2013 favored specialists, specialty Rx

2013 favored specialists, specialty Rx

The latest IMS Institute for Healthcare Informatics assessment of 2013's prescription drug use shows that 2.3% of prescriptions account for 30% of a patient's out-of-pocket prescription costs.